CD33 and acute myeloid leukemia: Current CAR T-cell therapeutic efforts in AML/MDS are, therefore, primarily devoted to testing such target antigens including the surface antigens CD33, CD117, CD123, and CD371 (Arai et al, 2018; Laborda et al, 2017; Mardiana and Gill, 2020; Myburgh et al, 2020; Tashiro et al, 2017; Wang et al, 2015).